Divalproex Sodium
Product Images NDC 55154-7145

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Divalproex Sodium (NDC 55154-7145). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Cardinal Health 107, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Bag Label (Bf6c7836 051e 4281 97c6 483901208c6f 00)

Bag Label (Bf6c7836 051e 4281 97c6 483901208c6f 00)
Divalproex Sodium 500 mg delayed-release tablets packaging label showing 10 tablets per package. The label includes storage instructions, a warning that the unit dose package is not child resistant and is intended for institutional use only, and pharmacy dispensing instructions. The label is from Cardinal Health 107, LLC and mentions the drug is manufactured by Rising Health and American Health Packaging.*
FDA Label Image

Bag Label (Bf6c7836 051e 4281 97c6 483901208c6f 01)

Bag Label (Bf6c7836 051e 4281 97c6 483901208c6f 01)
The image shows a text panel for Divalproex Sodium delayed-release tablets, USP 250 mg. It includes storage instructions, a usage warning indicating it is for institutional use only and not child-resistant, dispenser instructions to provide the Medication Guide, and packaging details by American Health Packaging distributed by Cardinal Health.*
FDA Label Image

Figure 1 (Divalproex Fig1)

Figure 1 (Divalproex Fig1)
A bar chart comparing percentage outcomes between placebo (PBO) and divalproex sodium delayed-release tablets (DVPX) across two studies. Study 1 (YMRS) shows 26% for PBO and 60% for DVPX, while Study 2 (MRS) shows 29% for PBO and 58% for DVPX, with significance indicated at p < 0.05.*
FDA Label Image

Figure 2 (Divalproex Fig2)

Figure 2 (Divalproex Fig2)
A cumulative percentage plot comparing Divalproex Sodium delayed-release tablets versus placebo. The vertical axis shows the percentage reduction in CPS rate ranging from -100% (worsening) to 100% (improvement), and the horizontal axis shows the percentage of patients from 0 to 100%. The chart illustrates treatment effects on CPS rate reduction in patients.*
FDA Label Image

Figure 3 (Divalproex Fig3)

Figure 3 (Divalproex Fig3)
A chart titled 'Figure 3' showing percentage reduction in CRPS rate on the vertical axis versus percentage of patients on the horizontal axis for Divalproex Sodium. The chart compares high dose (solid line) and low dose (dashed line) treatments, illustrating patient improvement and worsening trends.*
FDA Label Image

Figure 4 (Divalproex Fig4)

Figure 4 (Divalproex Fig4)
A bar chart titled 'Figure 4 Mean 4-week Migraine Rates' comparing migraine rates between placebo and Divalproex Sodium delayed-release tablets across two studies. The chart shows mean migraine rates on the y-axis and treatment groups on the x-axis, illustrating lower rates for Divalproex Sodium compared to placebo in both studies.*
FDA Label Image

Chemical Structure (Divalproex Str)

Chemical Structure (Divalproex Str)
Chemical structure of the active ingredient Divalproex Sodium, shown as a polymeric form with sodium ions and branched alkyl groups.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.